Figure 5.

KLRG1 therapy alone decreases 4T1 tumor burden in the lungs while double blockade therapy decreases subcutaneous 4T1 tumor burden

(A) Flow cytometry profile of 4T1 mammary carcinoma, unstimulated or treated with IFN-γ, and stained with an anti-E-cadherin mAb or an anti-PD-L1 mAb. (B) Balb/c mice were subcutaneously injected with 1 × 10⁵ 4T1 cells. Tumor-bearing mice were treated with isotype control, anti-KLRG1 mAb, anti-PD-1 mAb or anti-KLRG1 + anti-PD-1 mAbs on day 7, 10, 13, and 16 post-tumor cell implantation. Tumor volume was measured via caliper every three days (n = 13–14). (C) Balb/c mice were intravenously injected with 1 × 10⁵ 4T1 cells. Tumor-bearing mice were treated with isotype control, anti-KLRG1 mAb, anti-PD-1 mAb or anti-KLRG1 + anti-PD-1 mAbs on day 7, 10, 13, and 16 post-tumor cell injection. Tumors were quantified macroscopically on day 21 post-tumor cell injection (n = 11–12). (Data are representative (A) or pooled from two experiments (B-C), error bars indicate S.E.M.) *p < .05, **p < .01, ***p < .001, and ****p < .0001.